FGFR信号在SCLC和NSCLC中的作用：当前见解与治疗前景
The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives.
作者
作者单位
- School of Life Science and Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
摘要
中文
肺癌仍然是全球癌症相关死亡的主要原因，其特点是显著的生物学异质性和频繁的治疗失败。虽然肺癌根据细胞起源和临床行为大致分为小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC），但两者都依赖异常的信号网络来维持肿瘤生长和疾病进展。尽管生物标志物指导的治疗策略有所进展，针对单个基因改变的方法显示出有限的持久性，部分原因是肿瘤进化和细胞可塑性。在肺癌亚型共有的信号通路中，成纤维细胞生长因子（FGF）和成纤维细胞生长因子受体（FGFR）信号已被证明参与调节肿瘤增殖、血管生成和治疗适应性反应。在此，我们认为FGFR靶向治疗在肺癌中有限的临床成功反映了以改变为中心的靶向的局限性，而非缺乏生物学相关性。我们提出FGFR信号作为情境依赖的适应节点，其治疗意义在选择压力和获得性耐药下显现。
English
Lung cancer remains a leading cause of cancer related mortality worldwide and is characterized by marked biological heterogeneity and frequent therapeutic failure. Although lung cancer is broadly classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on distinct cellular origins and clinical behaviors, both entities rely on aberrant signaling networks to sustain tumor growth and disease progression. Despite advances in biomarker guided therapeutic strategies, approaches centered on individual genetic alterations have shown limited durability, in part due to tumor evolution and cellular plasticity. Among signaling pathways shared across lung cancer subtypes, fibroblast growth factor (FGF) and fibroblast growth factor receptor (FGFR) signaling has been implicated in regulating tumor proliferation, angiogenesis, and adaptive responses to therapy. Here, we argue that the limited clinical success of FGFR-targeted therapies in lung cancer reflects constraints of alteration-centered targeting rather than an absence of biological relevance. We propose that FGFR signaling functions as a context-dependent adaptive node, whose therapeutic significance emerges under selective pressure and acquired resistance.
分类与指标
- 研究类型
- 综述Meta
- 病种
- 肺癌
- JCR 分区
- Q1
- 影响因子
- 4.5
- 新锐分区
- 3区